176 related articles for article (PubMed ID: 38300709)
21. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.
Leclair HM; Tardif N; Paris A; Galibert MD; Corre S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708687
[TBL] [Abstract][Full Text] [Related]
22. BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.
Gebhardt K; Edemir B; Groß E; Nemetschke L; Kewitz-Hempel S; Moritz RKC; Sunderkötter C; Gerloff D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063443
[TBL] [Abstract][Full Text] [Related]
23. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
[TBL] [Abstract][Full Text] [Related]
24. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
25. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
[TBL] [Abstract][Full Text] [Related]
27. CDDO-Methyl Ester Inhibits BRAF Inhibitor Resistance and Remodels the Myeloid Compartment in BRAF-mutant Melanoma.
Torres GM; Jarnagin HC; Park C; Yang H; Kosarek NN; Bhandari R; Wang CY; Kolling FW; Whitfield ML; Turk MJ; Liby KT; Pioli PA
bioRxiv; 2023 Aug; ():. PubMed ID: 37577680
[TBL] [Abstract][Full Text] [Related]
28. Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.
Li B; Kong X; Post H; Raaijmakers L; Peeper DS; Altelaar M
J Proteome Res; 2021 Sep; 20(9):4381-4392. PubMed ID: 34343000
[TBL] [Abstract][Full Text] [Related]
29. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Audrito V; Messana VG; Moiso E; Vitale N; Arruga F; Brandimarte L; Gaudino F; Pellegrino E; Vaisitti T; Riganti C; Piva R; Deaglio S
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419372
[TBL] [Abstract][Full Text] [Related]
30. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
31. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
32. Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.
Lehraiki A; Cerezo M; Rouaud F; Abbe P; Allegra M; Kluza J; Marchetti P; Imbert V; Cheli Y; Bertolotto C; Ballotti R; Rocchi S
Cell Discov; 2015; 1():15030. PubMed ID: 27462428
[TBL] [Abstract][Full Text] [Related]
33. Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells.
Reddi KK; Guruvaiah P; Edwards YJK; Gupta R
Front Oncol; 2022; 12():937831. PubMed ID: 35785205
[TBL] [Abstract][Full Text] [Related]
34. Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma.
Hanly A; Gibson F; Nocco S; Rogers S; Wu M; Alani RM
JID Innov; 2022 Mar; 2(2):100090. PubMed ID: 35199090
[TBL] [Abstract][Full Text] [Related]
35. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
Prasad CP; Mohapatra P; Andersson T
Cancers (Basel); 2015 Sep; 7(3):1900-24. PubMed ID: 26393652
[TBL] [Abstract][Full Text] [Related]
36. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
37. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Koetz-Ploch L; Hanniford D; Dolgalev I; Sokolova E; Zhong J; Díaz-Martínez M; Bernstein E; Darvishian F; Flaherty KT; Chapman PB; Tawbi H; Hernando E
Pigment Cell Melanoma Res; 2017 May; 30(3):328-338. PubMed ID: 28140520
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.
Janostiak R; Malvi P; Wajapeyee N
iScience; 2019 Jun; 16():453-467. PubMed ID: 31229894
[TBL] [Abstract][Full Text] [Related]
40. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
